Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

NCT00884715 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Program was terminated for business reasons

Conditions

Carcinoid Syndrome

Interventions

DRUG: Octreotide

Sponsor

Endo Pharmaceuticals